icon-folder.gif   Conference Reports for NATAP  
 
  The Liver Meeting
Digital Experience
AASLD
November 13 - 16 - 2020
Back grey_arrow_rt.gif
 
 
 
Preliminary Results From a Phase 2 Study Evaluating VIR-2218 Alone and in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis B Infection
 
 
  AASLD 2021 Nov 12-15
 
Man-Fung Yuen1, Young-Suk Lim2, Daniel Cloutier3, Vaidehi Thanawala3, Ling Shen3, Andre Arizpe3, Chin Tay3, Sneha Gupta3, Andrea L Cathcart3, Carey Hwang3, Phillip S. Pang3, and Edward Gane4 1The University of Hong Kong, Hong Kong, China; 2University of Ulsan College of Medicine, Seoul, Korea; 3Vir Biotechnology Inc., San Francisco, California, USA; 4University of Auckland, Auckland, New Zealand

1123211

1123212

1123213

1123214

1123215

1123216

1123217